On January 3rd, 2024, the Xihu District held its grandest Science and Technology Innovation Conference in recent years. Gathering under one roof were nearly a thousand attendees, including leaders from all the four leadership  groups of the district government, heads of relevant provincial, municipal, and district departments, experts from local colleges and research institutions, as well as representatives from numerous technology enterprises and investment firms.

During the conference, outstanding science and technology companies were recognized, and Westlake Pharmaceuticals was honored with the title of the " Benchmark Project for University Economy" for 2023 in Xihu District.

At the meeting, Tong Guili, Secretary of the Party Committee of Department of Science and Technology of Zhejiang Province, Xu Weihua, Member of the Standing Committee of Hangzhou Municipal Party Committee, and Dong Yumin, Secretary of the CPC Xihu District Committee delivered speeches. Wang Jianyu, President of Hangzhou Institute for Advanced Study, UCAS, Xu Tian, Vice President of Westlake University, and Yu Feipeng, General Manager of Zhejiang University Holding Group Co., Ltd. delivered keynote addresses, collectively contributing their wisdom and strength to the creation of Xihu District as the premier destination for technology transfer and a source of innovation in science and technology.

At this conference, the Xihu District also unveiled its Action Plan for Establishing a Premier Destination for Technology Transfer and the Action Plan for an Innovation Circle around Universities; the Top 10 "Xihu District Science and Technology Pioneers Enterprises," "Benchmark Projects for University Economy," and "Outstanding Results of University Economy" in 2023 were spectacularly showcased; the first batch of "Science and Technology Combat Engineer" were introduced. Furthermore, 11 industry-university-research bases were recognized and granted the title of "New Model Industry-University-Research Bases" in Xihu District, and key scientific and technological cooperation projects and industry projects in Xihu District were signed on-site.

The development of West Lake Pharmaceuticals has received high recognition from the evaluation panel. The company's first product, Mprosevir, is currently undergoing the pre-market filing process before its official launch. Mprosevir is a novel small molecule oral antiviral drug against coronaviruses, having complete independent intellectual property rights. Its skeleton is entirely new and it is China's first non-covalent 3CL protease inhibitor.

Mprosevir is jointly researched and developed by Westlake University and Westlake Laboratories, and its transformation into a market-ready product is carried out by Westlake Pharmaceuticals. Its development process represents a successful exploration and implementation of the Westlake University innovation model.

With honors setting sail, embarking on a new year's journey, this accolade serves as both an affirmation of Westlake Pharmaceutical's past efforts and an inspiration to all employees. In the coming year, Westlake Pharmaceutical will remain true to its original mission, continue to strive forward with renewed vigor, and delve deeper into pathways for transforming academic achievements from universities into industrial applications, aiming to achieve even more groundbreaking progress from scratch!